Mirae Asset Global Investments will newly list the TIGER technology transfer bio active exchange-traded fund (ETF) on the 17th. It plans to build a portfolio centered on KOSDAQ bio corporations and use a strategy that actively adjusts stock weights by reflecting clinical momentum (upside potential) and global technology trends.
On the 16th, Mirae Asset Global Investments held a new listing webinar for the TIGER technology transfer bio active ETF and said the growth of the bio industry is likely to have a major impact on the flow of the KOSDAQ market. That is because a significant number of domestic bio corporations are listed on KOSDAQ.
In fact, bio accounts for about 40% of the KOSDAQ 150 index, the highest share among single industries. Mirae Asset Global Investments assessed that the outlook for KOSDAQ would also be positive due to the government's KOSDAQ revitalization policy and the inflow of policy funds.
For the TIGER technology transfer bio active ETF being launched this time, KOSDAQ stocks will make up about 80%–85% of the portfolio, and biotech will account for about 70%–80%. The weights may change depending on future healthcare market conditions.
With the patent for Keytruda expiring in 2028 and expirations continuing for major blockbuster drugs, global pharmaceutical companies have recently been moving aggressively to secure new pipelines to prepare for revenue gaps. Mirae Asset Global Investments said this shift in the structure of the global pharmaceutical industry could be an opportunity for domestic bio corporations.
As they expand external technology adoption, the technology transfer market is growing rapidly, which could strengthen the bargaining power of biotechs with technological competitiveness.
Song Jae-won, a senior manager at Mirae Asset Global Investments, said, "The pharma-bio industry is characterized by high volatility depending on clinical results and technology transfer momentum, so active stock selection is crucial," and added, "This ETF invests by comprehensively considering the competitiveness of clinical data, whether it is undervalued relative to corporate value, global technology trends, and market momentum."
It also laid out a specific method for managing the portfolio of the TIGER technology transfer bio active ETF. The company will track the flow of the global healthcare industry by referring to major conferences and industry events such as the JP Morgan Healthcare Conference, and use the clinical results of global competitor corporations developing the same technologies for risk management.
Senior Manager Song said, "Unlike other ETFs, we built the portfolio with a focus on biotech," and added, "Unlike passive types in the past, we can respond actively by seizing opportunities when undervalued to increase weights or selling decisively when negative factors are expected."